Abstracts Archive - Page 2021 of 2616 - ACR Meeting Abstracts

Abstract Number: 2094 • 2015 ACR/ARHP Annual Meeting
Identification of Gout Flare Using an Administrative Claims Based Algorithm
Lindsey MacFarlane¹, Daniel H. Solomon¹ and Seoyoung C. Kim², ¹Rheumatology, Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology; Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Gout is a common inflammatory arthritis characterized by repeated acute flares. The ability to accurately identify gout flares is critical for comparative effectiveness studies…
Abstract Number: 2095 • 2015 ACR/ARHP Annual Meeting
Dietary Patterns (DASH, Prudent, Western Diets) and the Risk of Gout in US Women – the Nurses Health Study
Jeewoong Choi¹, Na Lu², Yuqing Zhang³, Sharan K. Rai⁴, Gary C. Curhan⁵ and Hyon K. Choi², ¹Massachusetts College of Pharmacy and Health Sciences, Boston, MA, ²Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³BUSM, Boston, MA, ⁴Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, ⁵Renal Division, Brigham and Women's Hospital, Boston, MA
Background/Purpose: There is a remarkable, rising disease burden of gout and associated cardiovascular-metabolic comorbidities (e.g., hypertension in 74% and obesity in 53% of cases in…
Abstract Number: 2096 • 2015 ACR/ARHP Annual Meeting
Immune Dysregulation in Patients with TRNT1 Deficiency
Angeliki Giannelou¹, Qing Zhou², Hong-Wei Sun³, Dan Yang⁴, Susan Moir⁵, Jehad H. Edwan³, Wanxia L. Tsai³, Elisavet Serti⁶, Monique Stoffels², Deborah L. Stone⁷, Amanda K. Ombrello⁷, Karyl Barron⁵, Helen C. Su⁵, Abdullah Al Sonbul⁸, Sarita Joshi⁹, Kimberly Risma¹⁰, Lucie Sramkova¹¹, Martha M. Quezado¹², Katherine Calvo¹³, Abu-Asab Mones¹⁴, Gustavo Gutierrez-Cruz³, Massimo G. Gadina³, Markus Hafner³, Ivona Aksentijevich^2,15 and Daniel Kastner², ¹National Human Genome Research Institute, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²NIH/NHGRI, Metabolic, Cardiovascular, and Inflammatory Disease Genomics Branch, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, ⁵National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ⁶Immunology Section, Liver Diseases Branch, NIDDK, NIH, Bethesda, MD, ⁷National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ⁸King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia, ⁹Nationwide Children's Hospital, Columbus, OH, ¹⁰Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹¹Charles University 2nd Faculty of Medicine and UH Motol, Prague, Czech Republic, ¹²Laboratory of Pathology/National Cancer Institute, National Institutes of Health, Bethesda, MD, ¹³Department of Laboratory Medicine, National Institutes of Health, Bethesda, MD, ¹⁴National Eye Institute, National Institutes of Health, Bethesda, MD, ¹⁵Inflammatory Disease Section, National Human Genome Research Institute, Bethesda, MD
Background/Purpose: Next generation sequencing has led to the discovery of new diseases and molecules regulating immune function. Hypomorphic mutations in the TRNT1 gene cause a…
Abstract Number: 2097 • 2015 ACR/ARHP Annual Meeting
HLA-B27 Expression Profoundly Shapes the Host-Microbiota Metabolome
Mark Asquith¹, Patrick Stauffer², Sean Davin³, Stephen R. Planck⁴, Phoebe Lin⁵ and James T. Rosenbaum⁶, ¹OHSU, Portland, OR, ²Oregon Health & Science University, Portland, OR, ³Oregon Health and Science University, Portland, OR, ⁴Casey Eye Institute, Oregon Health & Science University, Portland, OR, ⁵Casey Eye Institute, Oregon Health and Science University, Portland, OR, ⁶Devers Eye Institute, Legacy Hospital system, Portland, OR
Background/Purpose: The intestinal microbiota plays a pivotal role in both host fitness and disease. Increasing evidence implicates microbial metabolites in the modulation of host immunity…
Abstract Number: 2098 • 2015 ACR/ARHP Annual Meeting
Prioritizing Likely Causative Genes in Genome-Wide Association Studies (GWAS) Identified Risk Loci for Immune-Mediated Inflammatory Disorders Using Cell-Type Specific Expression Quantitative Loci (eQTL) Information
Elisa Docampo¹, Ming Fang¹, Julia Dmitrieva¹, Emilie Théâtre¹, Mahmoud Elansary¹, Rob Mariman¹, Ann-Stephan Gori¹, Myriam Mni¹, François Crins², Wouter Coppieters², Edouard Louis³ and Michel Georges¹, ¹Unit of Animal Genomics, GIGA-R Université de Liège, Liège, Belgium, ²GenoTranscriptomics platform, GIGA-R Université de Liège, Liège, Belgium, ³Department of Gastroenterology, University Hospital CHU of Liège, Liège, Belgium
<h1> Background/Purpose: </h1> Immune-mediated inflammatory disorders (IMIDs) share many genetic risk factors. Pleiotropy may exist at different levels and most of the underlying mechanisms are…
Abstract Number: 2099 • 2015 ACR/ARHP Annual Meeting
Genome-Wide Association Study of Clinically-Defined Gout Identifies Multiple Risk Loci: A Clue for Future Companion Diagnostics of Gout
Hirotaka Matsuo¹, Ken Yamamoto², Hirofumi Nakaoka³, Akiyoshi Nakayama¹, Masayuki Sakiyama¹, Atsushi Takahashi^4,5, Takahiro Nakamura⁶, Yusuke Kawamura¹, Nobuyuki Hamajima⁷, Ituro Inoue⁸, Michiaki Kubo⁴, Kimiyoshi Ichida⁹, Hiroshi Ooyama¹⁰, Toru Shimizu¹¹ and Nariyoshi Shinomiya¹, ¹Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Tokorozawa, Japan, ²Department of Medical Chemistry, Kurume University School of Medicine, Kurume, Japan, ³Division of Human Genetics, Department of Integrated Genetics, National Institute of Genetics, Mishima, Japan, ⁴Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan, ⁵Research Center, National Cerebral and Cardiovascular Center, Suita, Japan, ⁶National Defense Medical College, Laboratory for Mathematics, Tokorozawa, Japan, ⁷Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁸Department of Integrated Genetics, National Institute of Genetics, Mishima, Japan, ⁹Department of Pathophysiology, Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan, ¹⁰Ryougoku East Gate Clinic, Tokyo, Japan, ¹¹Midorigaoka Hospital, Takatsuki, Japan
Background/Purpose: Gout, caused by hyperuricaemia, is a multifactorial disease. Recently, genome-wide association studies (GWASs) of gout have been reported; however, they included self-reported gout cases.…
Abstract Number: 2100 • 2015 ACR/ARHP Annual Meeting
Hypomethylation in Enhancer and Promoter Regions of Interferon Regulated Genes in Multiple Tissues Is Associated with Primary Sjögren’s Syndrome
Juliana Imgenberg-Kreuz¹, Johanna K Sandling^1,2, Jonas Carlsson Almlöf¹, Jessica Nordlund¹, Linnea Signér², Katrine B Norheim³, Roald Omdal³, Majia-Leena Eloranta², Lars Rönnblom², Ann-Christine Syvänen¹ and Gunnel Nordmark², ¹Molecular Medicine and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ²Rheumatology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ³Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway
Background/Purpose: Epigenetic modifications have emerged as important contributing factors in the pathogenesis of autoimmune diseases, including primary Sjögren’s syndrome (pSS), and may act as a…
Abstract Number: 2101 • 2015 ACR/ARHP Annual Meeting
HLA Associations in Mothers of Children with Cardiac Manifestations of Neonatal Lupus
Hannah C. Ainsworth¹, Carl D. Langefeld¹, Miranda C. Marion², Nathalie Costedoat-Chalumeau³, Antonio Brucato⁴, Jill P. Buyon⁵ and Robert M. Clancy⁵, ¹Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ²Biostatistical Sciences and Center for Public Health Genomics, Wake Forest University Health Sciences, Winston-Salem, NC, ³Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ⁴Internal Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy, ⁵Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Cardiac manifestations of neonatal lupus, comprising atrioventricular conduction defects and cardiomyopathy, occur in fetuses exposed to anti-Ro/SSA antibodies, and carry substantial mortality. There is…
Abstract Number: 2102 • 2015 ACR/ARHP Annual Meeting
Higher Persistence and Adherence with Combination Therapy with Tumor Necrosis Factor Inhibitor+Methotrexate Combination Versus Triple Therapy in US Veterans with Rheumatoid Arthritis
Brian Sauer¹, Chia-Chen Teng², Jianwei Leng³, Ted R. Mikuls⁴, Jeffrey R. Curtis⁵, Bradley S. Stolshek⁶, Derek Tang⁶ and Grant W. Cannon⁷, ¹IDEAS Center and Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ²HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ³Internal Medicine Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Amgen, Inc., Thousand Oaks, CA, ⁷Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT

Background/Purpose: Randomized controlled trials in RA have reported efficacy with both triple therapy (methotrexate [MTX] + hydroxychloroquine [HCQ] + sulfasalazine [SSZ]) and tumor necrosis factor…
Abstract Number: 2103 • 2015 ACR/ARHP Annual Meeting
Temporal Trends in Drug Prescription, Utilization and Costs Among Rheumatoid Arthritis (RA) Patients Show Wide Regional Variation Despite Universal Drug Coverage
Mark Tatangelo¹, Michael Paterson², George A. Tomlinson³, Nick Bansback⁴, Jessica Widdifield⁵, Tara Gomes² and Claire Bombardier⁶, ¹University of Toronto, Toronto, ON, Canada, ²Institute of Clinical Evaluative Sciences, Toronto, ON, Canada, ³Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ⁴Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, ⁵University Health Network, Toronto, ON, Canada, ⁶18 Strathearn Blvd, University of Toronto, Toronto, ON, Canada
Background/Purpose: Monitoring of drug use and costs can: describe trends in expenditures over time, identify regional variations in access and indicate physicians' uptake of best-practice…
Abstract Number: 2104 • 2015 ACR/ARHP Annual Meeting
Influence on Treatment Decision Making of Providing Numerical Ranges of Side-Effect Risks
Nick Bansback^1,2, Mark Harrison³, William G Dixon⁴ and Paul Han⁵, ¹Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, ²School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada, ³Centre for Health Evaluation and Outcomes Sciences, St Paul's Hospital, Vancouver, BC, Canada, ⁴Manchester Academic Health Sciences Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁵Center for Outcomes Research and Evaluation, Maine Medical Center, Portland, ME
Background/Purpose: Doctors and patients make treatment decisions after weighing benefits and harms. For harms, while people prefer treatments with smaller risks, how they react to…
Abstract Number: 2105 • 2015 ACR/ARHP Annual Meeting
Drug Survival and Cost Effectiveness in Patients on Reduced Dose Anti-TNF: Results of a 4 Year Prospective Observational Study
John Stack¹, Claire-Louise Murphy², Clara Bannon¹, Eithne Murphy¹, Trevor Duffy¹ and Maurice Barry¹, ¹Rheumatology, Connolly Hospital Blanchardstown, Dublin, Ireland, ²Rheumatology, Connolly Hospital Blanchardstow, Dublin, Ireland
Background/Purpose: Anti-TNF-α drugs are effective treatments for patients with inflammatory arthritis (IA). They are however expensive and their use carries a significant cost burden to…
Abstract Number: 2106 • 2015 ACR/ARHP Annual Meeting
Intensification to Triple Therapy Non-Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States from 2009 to 2014
Jeffrey A. Sparks¹, Alexis A. Krumme², Olga S. Matlin³, Gregory Brill², William H. Shrank³, Niteesh K. Choudhry² and Daniel H. Solomon^2,4, ¹Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³CVS Caremark, Woonsocket, RI, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Several trials suggest that triple therapy with non-biologic disease-modifying antirheumatic drugs (ttDMARD) has similar efficacy compared to biologic DMARDs (bDMARD) for patients with RA.…
Abstract Number: 2107 • 2015 ACR/ARHP Annual Meeting
Initiation of Combination Triple Therapy in Real World Clinical Practice Rarely Replicates the Protocols Used in Randomized Controlled Trials.
Grant W. Cannon¹, Chia-Chen Teng², Ted R. Mikuls³, Jeffrey R. Curtis⁴, Derek Tang⁵, Bradley S. Stolshek⁵ and Brian Sauer⁶, ¹Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ³Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT
Background/Purpose: Combination therapy with methotrexate (MTX), sulfasalazine (SUL), and hydroxychloroquine (HCQ) [triple therapy] is an effective treatment for rheumatoid arthritis (RA). Randomized controlled trials…
Abstract Number: 2108 • 2015 ACR/ARHP Annual Meeting
A Pragmatic Cluster-Randomized Controlled Trial of an Automated, Pharmacy-Based Intervention to Optimize Allopurinol Therapy in Gout
Ted R. Mikuls¹, T C Cheetham², Nazia Rashid², Gerald D. Levy³, Artak Kerimian⁴, KJ Low², Brian Coburn⁵, David T. Redden⁶, S. Louis Bridges Jr.⁷, Kenneth G. Saag⁶ and Jeffrey R. Curtis⁷, ¹Medicine, University of Nebraska Medical Center, Omaha, NE, ²Pharmacy Analytical Services, Kaiser Permanente Southern California, Downey, CA, ³Rheumatology, Kaiser Permanente Southern California, Downey, CA, ⁴Ambulatory Care Pharmacy, Kaiser Permanente Southern California, Downey, CA, ⁵Internal Medicine - Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Gout is a common form of inflammatory arthritis, often treated with allopurinol as a first-line urate lowering therapy. We have designed a large…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].